**Supplemental** **Table 1.**Baseline of the included studies.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Author(year) | Age（T/C）year | Male（T/C）% | Hypertention（T/C）% | DM（T/C）% | AF（T/C）% | CAD（T/C）% | Previous stroke（T/C）% |
| Gruber et al 2018[10] | 66/68 | 72/71 | 44/64 | 11/14 | 6/14 | None | None |
| Huang et al 2018[11] | 65/69 | None | None | None | None | None | None |
| Huo et al 2019[12] | 67/70 | 70/74 | 72/67 | 23/25 | None | None | None |
| Keller et al 2013[13] | 64/67 | None | None | None | None | None | None |
| Lee et al 2017[14] | 71/76 | 63/41 | 80/86 | 12/28 | 25/55 | 12/17 | 10/10 |
| Luo et al 2019[15] | 64/68 | 64/56 | 77/70 | 30/23 | 29/21 | 4/5 | 7/7 |
| Pan et al 2019[16] | 70/74 | 63/61 | 78/67 | 21/18 | 31/43 | 26/24 | 27/19 |
| Wu et al 2018[17] | 70/71 | 62/52 | 63/51 | 19/11 | 47/64 | None | None |
| Yu et al 2018[18] | 70/68 | 46/54 | 73/71 | 46/29 | 39/39 | 12/4 | None |
| Zhang et al 2019[19] | 64/64 | 60/58 | 58/63 | 13/20 | 35/46 | None | None |
| Zhao et al 2017[20] | 61/61 | 77/67 | 73/61 | 29/24 | 26/29 | None | None |

T:tirofiban group;C:control group; DM:diabetes mellitus;AF:atrial fabrillation;CAD:coronary heart disease;None:detailed information was not reported.